logo

Quality Control

Our priority, quality control

Our Quality Control Laboratories identify and analyze each batch of material received from our suppliers according to the specifications and analysis methods defined in our Drug Master Files (DMF). After the fulfillment of all analytical needs, the material are released to be used in production processes.

In the same way, each individual batch of active pharmaceutical ingredients manufactured by MOEHS
is analyzed according to pharmacopoeial procedures or, failing that, with developed and validated methods. The Quality Control laboratory applies the analysis methods and contrasts the specifications of the product with the documentation issued and approved by the Quality department. We keep analysis files for 11 years and sample preservation for 6 years. After releasing the batches by the Quality department, Quality Control issues the Certificate of Analysis and the labels that will identify the product drums. The Quality Control laboratory is equipped with the most modern analysis equipment and qualified analysts for the development of analytical tasks.

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.